Organic Synthesis Core Facility (OSCF)

The synthesis of modified and unmodified compounds in amounts that permit their availability for in vitro and in vivo assays and for secondary assays.

Some of the modifications that could be introduced will address such properties of molecules to render them more versatile. More precisely, we could introduce alterations that improve solubility, affinity, and specificity.

Large-scale chemical synthesis of compounds with demonstrated activity in primary bioassays in order to provide sufficient quantities for continued testing.

Fluorescent Labeling
The synthesis of assay development tools and reagents:
-Fluorescently labeled compounds
-Affinity labeled intermediates
-Cross linker-tethered molecules

Synthesis of modified nucleosides, nucleotides, as well as modified oligonucleotides (modified siRNAs, miRNAs, and damaged synthetic DNA).

Molecular modeling, homology modeling, and “in-silico” screening of virtual chemical libraries. This is backed by follow up organic synthesis of hits.

Perform structure-activity relationship (SAR) studies on validated pharmacophores to optimize targeting, specificity, bioavailability, while minimizing toxicity.

Precursors for radio-labeling experiments, as well as radio-labeled (11C, 3H, 125I, 32P …etc.) compounds for preclinical and clinical pharmacological evaluations.

Synthesis of modified nucleosides, nucleotides, as well as modified oligonucleotides (modified siRNAs, miRNAs, and damaged synthetic DNA).